Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure

Journal of Oncology Practice

Volumn 9, Issue 5, 2013, Pages 223-229

  Autio, Karen A ^b   Bennett, Antonia V ^b   Jia, Xiaoyu ^b   Fruscione, Michael ^b   Beer, Tomasz M ^b   George, Daniel J ^b   Carducci, Michael A ^b   Logothetis, Christopher J ^b   Kane, Robert C ^b   Sit, Laura ^b   Rogak, Lauren ^b   Morris, Michael J ^b   Scher, Howard I ^b   Basch, Ethan M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; DOCETAXEL;

ADULT; AGED; ARTICLE; BRIEF PAIN INVENTORY; CANCER PAIN; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; PAIN ASSESSMENT; PREVALENCE; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PAIN; PATIENT OUTCOME ASSESSMENT; PREVALENCE; PROSTATIC NEOPLASMS; SELF REPORT; TAXOIDS;

EID: 84892603274     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2013.000876     Document Type: Article

References (42)

1. Smith HS: Painful osseous metastases. Pain Physician 14:E373-E403, 2011
2. Armstrong AJ, Garrett-Mayer E, de Wit R, et al: Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16: 203-11, 2010
3. Halabi S, Vogelzang NJ, Kornblith AB, et al: Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26:2544- 2549, 2008
4. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996 (Pubitemid 26185452)
5. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506-2513, 1999 (Pubitemid 29368252)
6. Serafini AN, Houston SJ, Resche I, et al: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo- controlled clinical trial. J Clin Oncol 16: 1574-1581, 1998 (Pubitemid 28175783)
7. Lewington VJ, McEwan AJ, Ackery DM, et al: A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27: 954-958, 1991
8. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010
9. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005, 2011
10. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376: 1147-1154, 2010
11. Scher HI, Fizazi K, Saad F, et al: Enzalutamide prolongs survival in men with prostate cancer following chemotherapy. N Engl J Med 2012, doi:10.1056/ NEJMoa1207506
12. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004 (Pubitemid 39315318)
13. Parker C, Heinrich D, O'Sullivan JM, et al: Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Presented at the ASCO Genitourinary Cancers Symposium; February 2-4, 2012, San Francisco, CA (abstr 8)
14. Luckett T, Davidson PM, Green A, et al: Assessment and management of adult cancer pain: A systematic review and synthesis of recent qualitative studies aimed at developing insights for managing barriers and optimizing facilitators within a comprehensive framework of patient care. J Pain Symptom Manage doi:pii: S0885-3924(12)00470-8
15. Bateman E, Keefe D: Patient-reported outcomes in supportive care. Semin Oncol 38: 358-361, 2011
16. Basch E: Beyond the FDA PRO guidance: Steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 15: 401-403, 2012
17. Matza LS, Fallowfield LJ, Chung KC, et al: Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases. Support Care Cancer 20: 657-677, 2012
18. Scher HI, Morris MJ, Basch E, et al: End points and outcomes in castrationresistant prostate cancer: From clinical trials to clinical practice. J Clin Oncol 29: 3695-3704, 2011
19. Lipscomb J, Reeve BB, Clauser SB, et al: Patient-reported outcomes assessment in cancer trials: Taking stock, moving forward. J Clin Oncol 25:5133- 5140, 2007 (Pubitemid 350232295)
20. U.S. Food and Drug Administration: Draft guidance for industry: Qualification process for drug development tools. Issued October 2010. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM230597.pdf
21. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799-807, 2012
22. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012
23. Deisseroth A, Kaminskas E, Grillo J, et al: U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 18: 3212-3217, 2012
24. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502- 1512, 2004 (Pubitemid 39315317)
25. Southwest Oncology Group, Berry DL, Moinpour CM, et al: Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24: 2828-2835, 2006 (Pubitemid 46630582)
26. Melzack R: The McGill Pain Questionnaire: Major properties and scoring methods. Pain 1: 277-299, 1975
27. Ryan CJ, Smith MR, De Bono JS, et al: Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy- naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). http://meetinglibrary.asco.org/content/95300-114
28. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol doi:10.1016/s1470-2045(12)70379-0
29. Daut RL, Cleeland CS, Flanery RC: Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17: 197-210, 1983 (Pubitemid 13012221)
30. Atkinson TM, Mendoza TR, Sit L, et al: The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: Clinical trial endpoint considerations. Pain Med 11: 337-346, 2010
31. Kozminski MA, Neumann PJ, Nadler ES, et al: How long and how well: Oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. Med Decis Making 31: 380-385, 2011
32. Kirkbride P, Tannock IF: Trials in palliative treatment-have the goal posts been moved? Lancet Oncol 9: 186-187, 2008 (Pubitemid 351722934)
33. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008
34. Mack JW, Weeks JC, Wright AA, et al: End-of-life discussions, goal attainment, and distress at the end of life: Predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol 28: 1203-1208, 2010
35. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, et al: Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol 24: 4581-4586, 2006 (Pubitemid 46630955)
36. U.S. Food and Drug Administration: Presentation by Basch E: Methods used to assess and report pain-related endpoints. In: Report of the Oncology Drugs Advisory Committee meeting on NDA 021-801, Orplatna (satraplatin capsules); GPC Biotech Inc; July 24, 2007; Rockville, MD; pp 78-92. http://www.fda.gov/ ohrms/dockets/ac/07/transcripts/2007-4309t1-part3.pdf
37. Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer 50: 1913-1918, 1982 (Pubitemid 12001596)
38. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187-1197, 2012
39. Fisch MJ, Lee JW, Weiss M, et al: Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30: 1980-1988, 2012
40. Serlin RC, Mendoza TR, Nakamura Y, et al: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61: 277-284, 1995
41. Dworkin RH, Turk DC, Peirce-Sandner S, et al: Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 149: 177-193, 2010
42. Bennett AV, Jensen RE, Basch E: Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 62: 337-347, 2012